세계 유방암 진단 시장 규모는 2023년 42억 달러, 2030년까지 61억 6,000만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 연평균 6.67% 성장할 것으로 예상됩니다. 시장은 유방암 유병률 증가, 고령화 및 좌식 생활습관 증가, 기술 발전, 검진율 및 진단율을 높이기 위한 정부의 이니셔티브 증가 등의 요인으로 인해 2024-2030년의 예측 기간 동안 시장 성장을 가속할 것으로 보입니다.
유방암 진단 시장 역학
유방암 진단 시장의 주요 촉진요인 중 하나는 전 세계 유방암 발병률 증가입니다. 세계보건기구(WHO)의 2022년 자료에 따르면 2020년 전 세계적으로 230만 명의 여성이 유방암 진단을 받았습니다. 또한 2020년 말까지 지난 5년간 유방암 진단을 받은 생존 여성은 780만 명에 달하고, 세계에서 가장 높은 유병률을 보이는 암이 되었습니다고 합니다.
따라서 전 세계적으로 유방암 유병률이 증가하면 유방암 진단에 대한 수요가 증가하여 예측 기간(2024-2030년) 동안 유방암 진단 시장의 성장을 가속할 것으로 예상됩니다.
유방암 진단 시장의 성장을 이끄는 또 다른 주요 요인은 조기 검진 및 진단에 대한 인식을 높이기 위한 각국 정부의 이니셔티브이 증가하고 있다는 점입니다. 예를 들어, 세계보건기구(WHO)는 2022년 3월 세계 유방암 이니셔티브(Global Breast Cancer Initiative, GBCI)를 출범시켜 전 세계 유방암 사망률을 연간 2.5% 감소시키고, 2030년까지 70세 미만 여성의 유방암 사망률을 25%, 2040년까지 40% 감소시키겠다는 목표를 세웠습니다. 유방암의 징후, 증상, 조기 발견, 치료 등에 대한 정보를 제공하는 것은 유방암 진단과 치료에 대한 대중의 인식을 높여 유방암 진단 시장 수요를 증가시킬 것입니다.
그러나 유방암 진단의 높은 비용, 위양성 등 진단의 한계, 유방촬영술로 인한 과잉 진단이 불필요한 치료로 이어질 수 있다는 점은 유방암 진단 시장의 성장을 둔화시킬 수 있습니다.
코로나19 팬데믹은 유방암 진단 시장에 다소 부정적인 영향을 미쳤는데, 코로나19에 걸린 환자에 비해 암 및 기타 질병에 걸린 환자의 입원이 늦어지면서 유방암 진단 시장에 다소 부정적인 영향을 미쳤습니다. 엄격한 봉쇄 조치, 직원 부족, 마스크 및 PPE 키트 부족과 함께 병원의 유방암 환자 입원에 큰 영향을 미쳤습니다. 그러나 대중의 백신 접종과 의료 부문의 활동 재개로 인해 유방암 진단 시장은 모멘텀을 되찾고 예측 기간 동안 더 많은 성장을 보일 것으로 예상됩니다.
유방암 진단 시장 부문별 분석
유방암 진단 시장 유형별로는 유방촬영술, 초음파, 유방 MRI, CT 스캔과 같은 영상진단 기술을 통한 진단이 예측 기간 동안 가장 큰 비중을 차지할 것으로 예상됩니다. 이는 유방 조영술을 통한 유방 조직의 저선량 X선 영상, 유방암의 조기 발견 및 적시 발견, 화학 요법을 받을 위험 감소 등 영상 진단 기술과 관련된 다양한 이점 때문인 것으로 분석됩니다. 예를 들어, 2022년 7월 미국 국립암연구소(National Cancer Institute)에 따르면, 미국 예방 태스크포스(U.S. Preventive Task Force)는 50-74세 여성의 76.4%가 지난 2년 이내에 유방촬영술을 받을 것을 권장하고 있으며, 2030년까지 50-74세 여성의 77.1%가 유방암 검진을 받을 것으로 예상됩니다.
또한 2022년 1월, 듀크대 연구진은 유방 촬영 검사에서 암일 가능성이 있는 병변을 분석하여 환자가 침습적 생검을 받아야 하는지 여부를 판단하는 AI 플랫폼을 개발했습니다. 이 AI는 의심스러운 병변을 감지하여 유방 촬영 영상 판독 방법을 훈련하는 데 사용할 수 있으며, 의사가 의학적 판단을 내리는 데 도움이 될 수 있습니다. 또한, 이 AI 기술은 현명한 결정을 내리는 데 사용될 수 있으며, 영상 진단에 대한 수요를 증가시켜 2024-2030년의 예측 기간 동안 유방암 진단 기기 시장의 성장을 가속할 것으로 보입니다.
이 보고서는 세계 유방암 진단 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 제공합니다.
Breast Cancer Diagnostics Market By Product Type (Instrument, Reagent, And Consumables), By Type (Imaging, Lab Test), By End-User Type (Hospitals, Diagnostic Laboratories, Cancer Research Centers, Others), and by geography is expected to grow at a steady CAGR during the given forecast period owing to increase in the prevalence of breast cancer globally, growing geriatric population, the rising number of government initiatives to increase screening and diagnosis, and the increasing number of technological advancements.
The global Breast Cancer Diagnostics market was valued at USD 4.20 billion in 2023, growing at a CAGR of 6.67% during the forecast period from 2024 to 2030 to reach USD 6.16 billion by 2030. The breast cancer diagnostics market is witnessing positive growth owing to factors such as the increasing prevalence of breast cancer, increasing age and sedentary lifestyle, technological advancements, rising number of government initiatives to increase the rate of screening and diagnosis, thereby driving the growth of the breast cancer diagnostics market during the forecast period from 2024-2030.
Breast Cancer Diagnostics Market Dynamics:
One of the main drivers of the breast cancer diagnostics market is the increasing prevalence of breast cancer globally. As per the World Health Organization (WHO) 2022 data, in 2020 breast cancer was diagnosed in 2.3 million women globally. Further, as per the same source by the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the last 5 years, making it the world's most prevalent cancer.
Therefore, an increase in the prevalence of breast cancer around the world would lead to an increase in the demand for breast cancer diagnostics, thereby propelling the growth of the breast cancer diagnostics market during the forecast period (2024-2030).
Moreover, another key factor that is responsible for the growth of the breast cancer diagnostics market is the rising number of initiatives taken by specific national governments to increase awareness about early screening and diagnosis. For instance, in March 2022, WHO launched a Global Breast Cancer Initiative (GBCI) to reduce global breast cancer mortality by 2.5% per year, which would prevent 25% of breast cancer deaths by 2030 and 40% by 2040 among women under 70 years of age. Providing information about signs, symptoms, early detection, treatment, etc. of breast cancer would aware public of breast cancer diagnosis and treatment which would increase the demand for the breast cancer diagnostics market.
However, the high cost of diagnosis of breast cancer, limitations in diagnosis like false-positive results, and overdiagnosis with mammogram leads to unnecessary treatments which can slow down the breast cancer diagnostics market growth.
The COVID-19 pandemic has slightly impacted the market for breast cancer diagnostics market negatively as hospital admissions for patients suffering from cancers and other disorders were not a priority in comparison to the patients suffering from coronavirus. Along with strict lockdown regulations, a lack of staff, and a shortage of masks and PPE kits made a huge impact on breast cancer patient admissions in hospitals. However, with the masses being vaccinated and the resumption of activities in the healthcare sector, the breast cancer diagnostics market has picked momentum and is expected to further grow during the forecast period.
Breast Cancer Diagnostics Market Segment Analysis:
Breast cancer diagnostics market by product type (instrument, reagent, and consumables), type (imaging, lab test), end-user type (hospitals, diagnostic laboratories, cancer research centers, others), and by geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the type segment of the breast cancer diagnostics market, diagnosis through imaging techniques such as mammography, ultrasound, breast MRI, and CT scan is expected to hold a significant share during the forecast period, owing to the various benefits associated with them such as low-dose x-ray image of breast tissue through a mammogram, early and timely detection of breast cancer, thereby also reducing the risks of undergoing chemotherapy. For example, according to the National Cancer Institute July 2022, U.S. preventive task force recommends that 76.4% of women aged 50-74 years had mammography within the past 2 years. By 2030, 77.1 % proportion of women aged 50-74 years would have received breast cancer screening.
In addition, in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians to take health care decisions. Furthermore, this AI technology could be used for making wise decisions, increasing the demand for image diagnosis, thus driving the growth of the breast cancer diagnostics devices market during the forecast period from 2024-2030.
North America is expected to dominate the overall Breast Cancer Diagnostics Market:
Among all the regions, North America is expected to dominate the global breast cancer diagnostics market during the forecast period from 2024-2030. Factors such as aging, race, and ethnicity drive breast cancer which increase the demand for breast cancer diagnostics in the North America market.
According to the American Cancer Society (2023), in January 2022 in the US, variations in breast cancer could be seen due to differences in racial and ethnic groups. The age of diagnosis was slightly younger for black women (age 60), followed by white women (age 63). Black women also have a higher death rate in this as 1 in 5 black women have triple-negative breast cancer which was more than in any other racial/ethnic group.
Furthermore, aging is the biggest risk factor for breast cancer. As people grow older, the chances of developing cancer increase. According to the same source in February 2022, 1 out of 8 women younger than 45 developed invasive breast cancer, and 2 out of 3 invasive breast cancers were found in women 55 or older.
The Breast Cancer Organization (2023) also mentioned that as of January 2022, more than 3.8 million women had a history of breast cancer in the US. One in eight American women (13%) was expected to develop invasive breast cancer at some point in their lives on average. In men, 2,710 new cases of invasive breast cancer are expected to be diagnosed by 2022 end in the US.
Therefore, the rising prevalence of breast cancer, aging, race, and ethnicity would result in the rising demand for breast cancer diagnostics which in turn would provide a conducive growth environment for the North America breast cancer diagnostics market.
Breast Cancer Diagnostics Market Key Players:
Some of the key market players operating in the breast cancer diagnostics market include Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCine, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.
Recent Developmental Activities in the Breast Cancer Diagnostics:
In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography device).
In Jan 2022, UE LifeSciences entered into a definitive distribution agreement with Siemens Healthineers, adding its flagship device iBreastExam to Siemens' 360-degree breast care product portfolio for the U.S. market.
In Nov 2022, Kheiron Medical Technologies Launched RSViP to Help U.S. Breast Screening Programs Tackle Backlogs Worsened by COVID-19.
In Jan 2022, Kheiron's AI Breast Screening Solution Mia Receives Regulatory Clearance in Australia and New Zealand.
Key Takeaways from the Breast Cancer Diagnostics Market Report Study
Target Audience who can be benefited from this Breast Cancer Diagnostics Market Report Study
Frequently Asked Questions for Breast Cancer Diagnostics:
Breast cancer diagnostics are used detect breast cancer in men and women experiencing its signs and symptoms. Early diagnosis could improve cancer treatment by providing care at the earliest stage possible.
The global Breast Cancer Diagnostics market was valued at USD 4.20 billion in 2023, growing at a CAGR of 6.67% during the forecast period from 2024 to 2030 to reach USD 6.16 billion by 2030.
The breast cancer diagnostics market is witnessing positive market growth owing to the factors such as, increasing prevalence of breast cancer, Increasing age and sedentary lifestyle, inherited breast cancer genes, race, ethnicity, technological advancements, and government initiatives to increase the rate of screening and diagnosis.
Some of the key market players operating in the breast cancer diagnostics market include Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCine, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.
North America is expected to dominate the global breast cancer diagnostics market. Factors contributing to its growth are the increasing prevalence of breast cancer due to aging, race, ethnicity, and others, increasing the demand for breast cancer diagnostics, thus driving the breast cancer diagnostics market growth in North America region.